Tin tức & Cập nhật

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), anlotinib plus pepulimab appears to significantly increase progression-free survival (PFS) and overall survival (OS) compared with sorafenib, as shown in the results of the phase III APOLLO study conducted in China.

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

The addition of granulocyte colony-stimulating factor (GCSF) to prednisolone results in improved steroid responsiveness and prolonged survival with fewer infections and new-onset complications among patients with severe alcohol-associated hepatitis (SAH), a study has shown.

Treatment with the bivalent fibroblast growth factor 21 (FGF21) analogue efruxifermin falls short of improving fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction–associated steatohepatitis (MASH), according to a phase 2b study.

The long-acting, bivalent fibroblast growth factor 21 analogue efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) in the phase 2b SYMMETRY trial.

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

ĐỘT QUỴ NÃO LÀ NGUYÊN NHÂN THƯỜNG GẶP THỨ BA GÂY TỬ VONG TRÊN TOÀN CẦU theo báo cáo Gánh nặng Bệnh tật Toàn cầu năm 2021. THUỐC CHỐNG ĐÔNG ĐƯỜNG UỐNG TÁC DỤNG TRỰC TIẾP (DOAC) đã được chỉ định để phòng ngừa và điều trị nhiều bệnh lý tim mạch, đặc biệt là phòng ngừa đột quỵ hoặc thuyên tắc huyết khối hệ thống ở bệnh nhân rung nhĩ có một hoặc nhiều yếu tố nguy cơ đột quỵ. KHỞI TRỊ SỚM DOAC KHÔNG THUA KÉM KHỞI TRỊ MUỘN SAU ĐỘT QUỴ là nhận định rút ra từ các nghiên cứu ngẫu nhiên có đối chứng như TIMING, ELAN, OPTIMAS.